Fairvalue-Calculator Fairvalue-Calculator
EN DE

Metagenomi Therapeutics, Inc (MGX) Fair Value & Analysis

Healthcare · US · Market cap $45.2M

Price$1.24
Fair Value$2.74
Upside+121.0%
Quality95/100
Evidence: Low Range $1.81 – $3.42

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Metagenomi Therapeutics, Inc (MGX) currently trades at $1.24, while our model-based Fair Value estimate is $2.74 — implying the stock looks roughly 121.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Metagenomi Therapeutics, Inc (MGX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.74 versus a price of $1.24 — about +121% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MGX?
Our 21-model fair value for Metagenomi Therapeutics, Inc is $2.74 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.24.
What is the quality score of MGX?
Metagenomi Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.